Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 8731 https://www.aldeyra.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics Inc

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Nov 27th, 2023 9:07 pm
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap - Nov 1st, 2023 11:05 am
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More - Oct 18th, 2023 12:30 pm
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback - Oct 17th, 2023 2:13 pm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has caught the attention of institutional investors who hold a sizeable 43% stake - Sep 15th, 2023 10:50 am
15 Most Shorted Stocks That Are Loved By Analysts - Aug 28th, 2023 2:22 pm
Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? - Jul 20th, 2023 1:55 pm
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum - Jul 6th, 2023 11:00 am
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa - Jun 29th, 2023 11:00 am
The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win - Jun 29th, 2023 9:20 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa - Jun 28th, 2023 8:01 pm
Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo - Jun 27th, 2023 4:03 pm
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough - Jun 27th, 2023 11:00 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough - Jun 26th, 2023 8:01 pm
Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - Jun 23rd, 2023 11:00 am
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 - Jun 21st, 2023 1:34 pm
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study - Jun 16th, 2023 2:26 pm
Why Aldeyra Therapeutics Stock Is Trading Higher Today - Jun 15th, 2023 6:52 pm
Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis - Jun 15th, 2023 11:00 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis - Jun 14th, 2023 8:01 pm